title: Comparison of the clinical efficacy of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism: a randomized controlled study.
abstract: OBJECTIVE
  To compare the effectiveness of flutamide and spironolactone plus Diane 35 in the treatment of idiopathic hirsutism (IH).
  
  
  METHODS
  Prospective randomized clinical study.
  
  
  METHODS
  Social Security Agency, Aegean Obstetrics and Gynecology Teaching Hospital, Department of Reproductive Endocrinology and Infertility, a tertiary referral center.
  
  
  METHODS
  Eighty women with IH who had been admitted to our center.
  
  
  METHODS
  Patients were randomly and equally assigned to receive flutamide (250 mg/d for the first 10 days of the cycle) and spironolactone plus Diane 35 (spironolactone 100 mg/d; Diane 35 is a combination tablet of 2 mg cyproterone acetate and 35 microg ethinylestradiol/d) for 9 months.
  
  
  METHODS
  Modified Ferriman-Gallwey (F-G) score and hormonal profile before treatment and at the end of treatment.
  
  
  RESULTS
  In spite of the fact that there were no statistically significant differences in modified F-G scores in between the two groups, a significant decrease in modified F-G scores was observed in the flutamide (from 19.93 +/- 4.31 to 15.58 +/- 4.28) and spironolactone plus Diane 35 (from 18.77 +/- 3.76 to 14.54 +/- 3.29) groups. There were also no differences between the two groups with respect to hormonal profiles including serum FSH, LH, free T, 17-OH-progesterone, and DHEAS levels. No major side effect, including liver toxicity, was observed in either group.
  
  
  CONCLUSIONS
  Our data suggest that both therapies have similar effectiveness in the treatment of IH.
authors.affiliation: Social Security Agency, Department of Reproductive Endocrinology and Infertility, Aegean Obstetrics and Gynecology Teaching Hospital, Izmir, Turkey.
authors.forename: M Murat
authors.initials: MM
authors.lastname: Inal
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Yildirim
authors.forename: C Eftal
authors.initials: CE
authors.lastname: Taner
mesh_terms: D000328:Adult; D000726:Androgen Antagonists / Q000008:administration & dosage*; D017373:Cyproterone Acetate / Q000008:administration & dosage*; D004232:Diuretics / Q000008:administration & dosage*; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D004997:Ethinyl Estradiol / Q000008:administration & dosage*; D005260:Female; D005485:Flutamide / Q000008:administration & dosage*; D006628:Hirsutism / Q000188:drug therapy*; D006801:Humans; D011085:Polycystic Ovary Syndrome / Q000150:complications; D011446:Prospective Studies; D013148:Spironolactone / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists; D004232:Diuretics; D004338:Drug Combinations; D013148:Spironolactone; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; C032640:Cyproterone acetate, ethinyl estradiol drug combination; D005485:Flutamide